European Regulators Advise Revoking Autoimmune Drug Tavneos Authorization

European regulators have recommended revoking the marketing authorization for the autoimmune drug Tavneos (avacopan). This decision follows concerns from the U.S. FDA, with the European Medicines Agency's committee concluding that the drug's health risks, including liver injury, outweigh its therapeutic benefits.